Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Müller M, Posch F, Kiem D, Barth D, Horvath L, Stotz M, Schaberl-Moser R, Pichler M, Greil R, Jost PJ, Seeber A, Amann A, Schlick K, Gerger A, Riedl JM.
Müller M, et al. Among authors: kiem d.
Ther Adv Med Oncol. 2021 Sep 30;13:17588359211039930. doi: 10.1177/17588359211039930. eCollection 2021.
Ther Adv Med Oncol. 2021.
PMID: 34616490
Free PMC article.